Amerikaanse aandelen« Terug naar discussie overzicht

1. Danycactus 25 januari 2010 21:49

   auteur info

   •    Danycactus

     Lid sinds: 22 sep 2009

     Laatste bezoek: 01 aug 2024

   •    Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 42

   Zou veel belovend zijn voor 2010
   www.cytoritx.com/Home.aspx
   
   moneymorning.com/2010/01/20/cytori-th...
   
   www.beursduivel.be/forum.php?page=top...,_de_nieuwe_BI..&laatste=true
2. [verwijderd] 12 maart 2010 17:28

   auteur info

   •    [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   •    Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Real-Time: $6.25 Down 1.25 (-16.67%)
   
   Prev Close: $7.50
   
   Day's Range: $5.50 - $7.00
   
   52wk Range: $1.42 - $9.50
   
   Volume: 2,823,983
   
   UPDATE 1-Cytori posts wider-than-expected Q4 loss, shares fall
   
   * Q4 loss/shr $0.24 vs est. loss/shr $0.16
   
   * Q4 rev rise 32 pct
   
   * Shares fall as much as 27 pct
   
   March 12 (Reuters) - Cytori Therapeutics Inc <CYTX.O> posted a wider-than-expected quarterly loss, hurt by higher expenses, sending shares down as much as 27 percent.
   
   For the fourth quarter, the company posted a net loss of $9.5 million, or 24 cents a share, compared with $6.5 million, or 22 cents a share, a year ago.
   
   Total revenue rose 32 percent at $2.9 million. Operating expenses rose about 42 percent to $11.2 million.
   
   Analysts on average expected the company to post a loss of 16 cents a share, on revenue of $1.9 million, according to Thomson Reuters I/B/E/S.
   
   Shares of the company, which fell 27 percent to $5.50 in early trade, pared some losses and were down 18 percent at $6.19 in morning trade on Nasdaq.
   
   www.dailyfinance.com/quotes/cytori-th...
   
   finviz.com/screener.ashx?v=341&f=ind_...
   
   Skip
3. [verwijderd] 7 mei 2010 14:44

   auteur info

   •    [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   •    Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   www.xconomy.com/san-diego/2010/05/07/...
   
   Cytori Heartened by Cell Therapy in Two Small Studies of Cardiac Patients
   Denise Gellene 5/7/10
   San Diego-based Cytori Therapeutics (NASDAQ: CYTX) is announcing encouraging results this morning from two small, placebo-controlled studies of its fat-derived regenerative cell therapy in cardiac patients. The double-blind studies, which were conducted in Europe, should pave the way for a larger test in heart attack patients, the company says.
   
   The first study involved 27 chronic heart disease patients; 18 got cell therapy and 9 received a placebo. After six months, the treatment group showed improvements on key measures of oxygen consumption and aerobic capacity. By contrast, the placebo group’s performance on those key measures declined. The differences between groups are statisically significant, the company says.
   
   Specifically, the treated group showed an average 3.6 percent improvement in maximum oxygen consumption compared to an average 18.4 percent decline in the placebo group. Aerobic capacity in the treated group as measued by metabolic equivalents (METS) rose .2 points compared to a drop of .8 points in the placebo group.
   
   The second study involved 14 heart attack patients; roughly two-thirds received cell therapy within 24 hours after arriving at the emergency room, the remaining patients were in a placebo group. Although the study was too small to demonstrate statistical validity, the treatment group showed a stronger improvement trend.
   
   No serious side effects related to treatment were seen in trials, Cytori CEO Marc Hedrick tells me.
   
   It’s important to note that each study excluded …Next Page »
   
   Denise Gellene is a former Los Angeles Times science writer and regular contributor to Xconomy. You can reach her at dgellene@xconomy.com